Skip to main content

Table 3 Treatment response in asthma patients with anti-IL 5/IL5R (reslizumab, mepolizumab or benralizumab) therapy and anti-IgE (omalizumab) therapy. Patients with discontinued biological therapy were included in the analyses

From: A comparison of biologicals in the treatment of adults with severe asthma – real-life experiences

  Anti-IL5/IL5R (reslizumab, mepolizumab, benralizumab) N = 42   Anti-IgE (omalizumab) N = 22  
Baseline Change P Baseline Change P
Mean daily OCS dose (mg) a 7.07 (0–40. SD 7.13) −3.00 (−35–25. SD 7.91) 0.020 4.82 (0–20. SD 6.50) −2.29 (−20–0. SD 5.80) 0.085
Courses of OCS b 4.21 (0–12. SD 2.75) −2.77 (−7.64–1. SD 2.81) 1.47 e−07 2.50 (0–6. SD 1.56) −1.32 (−4–10. SD 2.01) 0.007
Courses of antibiotics b 1.40 (0–5. SD 1.42) −0.69 (−5–7. SD 2.08) 0.040 0.95 (0–3. SD 0.93) − 0.23 (− 3–5. SD 1.47) 0.488
Emergency room visits b 0.62 (0–8. SD 1.63) −0.29 (−6–4. SD 1.30) 0.159 0.18 (0–1. SD 0.39) 0.18 (− 1–5. SD 1.19) 0.492
Hospitalisations b 0.52 (0–8. SD 1.42) − 0.20 (−8–4. SD 1.63) 0.448 0.45 (0–2. SD 0.66) 0.00 (− 1–5. SD 1.21) 1.00
Sick leaves b 0.93 (0–6. SD 1.72) − 0.58 (− 6–6. SD 1.86) 0.053 0.59 (0–4. SD 1.03) −0.14 (− 3–11. SD 1.18) 0.602
Total number of exacerbation events c 7.57 (1–26. SD 5.59) −4.43 (− 22–13. SD 6.24) 4.79 e− 05 4.68 (0–11. SD 3.40) −1.50 (− 7–21. SD 5.55) 0.229
Blood eosinophil count (E9/litre) 0.45 (0.03–1.84. SD 0.37) − 0.39 (− 1.79–0.01. SD 0.38) 2.36 e− 07 0.43 (0–1.34. SD 0.41) −0.08 (− 0.61–0.52. SD 0.41) 0.433
Mean FEV1 (litres) 2.27 (1.0–4.2. SD 0.78) 0.17 (− 0.5–1.3. SD 0.41) 0.014 2.83 (1.5–4.2. SD 0.86) 0.05 (− 0.6–1.3. SD 0.54) 0.720
ACT (mean) d 15.63 (8–23. SD 4.28) 4.46 (− 15–13. SD 5.81) 0.0005 13.40 (7–22. SD 4.82) 8.50 (2–17. SD 5.63) 0.015
Exhaled nitric oxide (mean) (ppb) 28.17 (5–110. SD 28.98) − 4.78 (− 68–40.1. SD 18.83) 0.759 35.66 (5–123. SD 36.30) − 12.63 (− 71–21.5. SD 36.56) 0.592
Serum total IgE (mean) (kU/litre) e 290.85 (8–4672. SD 786.18) 160 (− 304–1693. SD 551.61) 0.424 313.36 (14–845. SD 248.76) 77.83 (− 24–369. SD 133.38) 0.249
  1. aOCS = per oral corticosteroid
  2. bNumber due to asthma during the last 12 months
  3. cdefined as the sum of courses of oral corticosteroid and antimicrobial drugs, sick leaves, hospitalisations and emergency room visits due to asthma during the last 12 months
  4. dACT = Asthma control test, maximal score 25 points
  5. eIn the hospital district that this study was conducted, serum total IgE is systematically measured before initiation of biological therapy but not during therapy. As a result, serum total IgE levels during therapy were available only occasionally and the change in the serum IgE level cannot be used as treatment effect measurement